{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T12:11:22Z","timestamp":1774440682831,"version":"3.50.1"},"reference-count":132,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:p>The present review discusses current developments and outcomes of renal transplantation in systemic amyloidosis. Amyloidosis can wreak havoc on the architecture and functioning of the kidneys, leading to end-stage renal disease. In recent years, the available treatments, especially for light-chain amyloidosis but also for several of the underlying inflammatory diseases that cause amyloid A amyloidosis have expanded leading to prolonged survival albeit frequently with renal failure. At the same time, there are also increasing numbers of patients diagnosed with one of the inherited forms of amyloidosis for which currently there is no targeted treatment available and, in some cases, renal failure is unavoidable. Due to the complex nature of the pathophysiology and treatment of these diseases, it can be very challenging for the clinician to determine whether or not it is appropriate to refer an affected individual for kidney transplantation. Determining eligibility criteria, as well as peritransplant and posttransplant management, requires a multidisciplinary approach with close monitoring and follow-up.<\/jats:p>","DOI":"10.1097\/tp.0000000000003170","type":"journal-article","created":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T20:30:55Z","timestamp":1581539455000},"page":"2035-2047","source":"Crossref","is-referenced-by-count":13,"title":["Kidney Transplantation in Systemic Amyloidosis"],"prefix":"10.1097","volume":"104","author":[{"given":"Avital","family":"Angel-Korman","sequence":"first","affiliation":[{"name":"Renal Section, Department of Medicine, Boston University School of Medicine, Boston, MA."},{"name":"Amyloidosis Center, Boston University School of Medicine, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Havasi","sequence":"additional","affiliation":[{"name":"Renal Section, Department of Medicine, Boston University School of Medicine, Boston, MA."},{"name":"Amyloidosis Center, Boston University School of Medicine, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,2,11]]},"reference":[{"key":"R1-20231002","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1681\/ASN.2006050460","article-title":"Amyloidosis-associated kidney disease.","volume":"17","author":"Dember","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R2-20231002","first-page":"45","article-title":"Primary systemic amyloidosis: clinical and laboratory features in 474 cases.","volume":"32","author":"Kyle","year":"1995","journal-title":"Semin Hematol"},{"key":"R3-20231002","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/ckj\/sfu117","article-title":"The clinical features and outcomes of systemic AL amyloidosis: a cohort of 231 Chinese patients.","volume":"8","author":"Huang","year":"2015","journal-title":"Clin Kidney J"},{"key":"R4-20231002","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/ajh.23333","article-title":"Clinical features and treatment outcome of primary systemic light-chain amyloidosis in Korea: results of multicenter analysis.","volume":"88","author":"Jun","year":"2013","journal-title":"Am J Hematol"},{"key":"R5-20231002","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","article-title":"Molecular mechanisms of amyloidosis.","volume":"349","author":"Merlini","year":"2003","journal-title":"N Engl J Med"},{"key":"R6-20231002","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0014-5793(01)02480-2","article-title":"Transthyretin amyloidosis: a tale of weak interactions.","volume":"498","author":"Saraiva","year":"2001","journal-title":"FEBS Lett"},{"key":"R7-20231002","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1110\/ps.29002","article-title":"The solution structure of human beta2-microglobulin reveals the prodromes of its amyloid transition.","volume":"11","author":"Verdone","year":"2002","journal-title":"Protein Sci"},{"key":"R8-20231002","doi-asserted-by":"crossref","first-page":"16115","DOI":"10.1073\/pnas.1306621110","article-title":"Pathogenetic mechanisms of amyloid A amyloidosis.","volume":"110","author":"Simons","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R9-20231002","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1146\/annurev.med.51.1.543","article-title":"The genetics of the amyloidoses.","volume":"51","author":"Buxbaum","year":"2000","journal-title":"Annu Rev Med"},{"key":"R10-20231002","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/circ.104.14.1594","article-title":"Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts.","volume":"104","author":"Liao","year":"2001","journal-title":"Circulation"},{"key":"R11-20231002","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1161\/01.RES.0000126569.75419.74","article-title":"Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress.","volume":"94","author":"Brenner","year":"2004","journal-title":"Circ Res"},{"key":"R12-20231002","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1182\/blood-2013-10-525634","article-title":"A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis.","volume":"123","author":"Diomede","year":"2014","journal-title":"Blood"},{"key":"R13-20231002","doi-asserted-by":"crossref","first-page":"7576","DOI":"10.1523\/JNEUROSCI.21-19-07576.2001","article-title":"Familial amyloid polyneuropathy: receptor for advanced glycation end products-dependent triggering of neuronal inflammatory and apoptotic pathways.","volume":"21","author":"Sousa","year":"2001","journal-title":"J Neurosci"},{"key":"R14-20231002","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/13506129.2018.1549825","article-title":"Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee.","volume":"25","author":"Benson","year":"2018","journal-title":"Amyloid"},{"key":"R15-20231002","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1093\/ndt\/gfq831","article-title":"Renal amyloidosis revisited: amyloid distribution, dynamics and biochemical type.","volume":"26","author":"Hopfer","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"R16-20231002","doi-asserted-by":"crossref","first-page":"E458","DOI":"10.1002\/ajh.24464","article-title":"Validation of new renal staging system in AL amyloidosis treated with high dose melphalan and stem cell transplantation.","volume":"91","author":"Havasi","year":"2016","journal-title":"Am J Hematol"},{"key":"R17-20231002","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis.","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood"},{"key":"R18-20231002","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.","volume":"30","author":"Palladini","year":"2012","journal-title":"J Clin Oncol"},{"key":"R19-20231002","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.kint.2018.09.021","article-title":"Long-term outcome of kidney transplantation in AL amyloidosis.","volume":"95","author":"Angel-Korman","year":"2019","journal-title":"Kidney Int"},{"key":"R20-20231002","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/ki.2012.414","article-title":"The diagnosis and characteristics of renal heavy-chain and heavy\/light-chain amyloidosis and their comparison with renal light-chain amyloidosis.","volume":"83","author":"Nasr","year":"2013","journal-title":"Kidney Int"},{"key":"R21-20231002","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2215\/CJN.08720811","article-title":"Transthyretin amyloidosis and the kidney.","volume":"7","author":"Lobato","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"R22-20231002","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","article-title":"Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease.","volume":"15","author":"Adams","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"R23-20231002","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3109\/13506120308998998","article-title":"Tabulation of human transthyretin (TTR) variants, 2003.","volume":"10","author":"Connors","year":"2003","journal-title":"Amyloid"},{"issue":"Suppl 1","key":"R24-20231002","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3109\/13506129.2011.574354071","article-title":"Combined liver-kidney transplantation in familial amyloidotic polyneuropathy TTR V30M: nephrological assessment.","volume":"18","author":"Lobato","year":"2011","journal-title":"Amyloid"},{"key":"R25-20231002","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/ndt\/18.3.532","article-title":"Familial ATTR amyloidosis: microalbuminuria as a predictor of symptomatic disease and clinical nephropathy.","volume":"18","author":"Lobato","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"R26-20231002","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/13506120600722662","article-title":"Value of renal biopsy in the prognosis of liver transplantation in familial amyloid polyneuropathy ATTR Val30Met patients.","volume":"13","author":"Oguchi","year":"2006","journal-title":"Amyloid"},{"key":"R27-20231002","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1182\/blood-2009-06-223792","article-title":"Hereditary fibrinogen A alpha-chain amyloidosis: phenotypic characterization of a systemic disease and the role of liver transplantation.","volume":"115","author":"Stangou","year":"2010","journal-title":"Blood"},{"key":"R28-20231002","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.ekir.2016.11.005","article-title":"Renal amyloidosis associated with 5 novel variants in the fibrinogen A alpha chain protein.","volume":"2","author":"Rowczenio","year":"2017","journal-title":"Kidney Int Rep"},{"key":"R29-20231002","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3109\/13506129.2013.781998","article-title":"Hereditary amyloidosis caused by R554L fibrinogen A\u03b1-chain mutation in a Spanish family and review of the literature.","volume":"20","author":"Haidinger","year":"2013","journal-title":"Amyloid"},{"key":"R30-20231002","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1681\/ASN.2008060614","article-title":"Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis.","volume":"20","author":"Gillmore","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R31-20231002","doi-asserted-by":"crossref","first-page":"4313; author reply 4314","DOI":"10.1182\/blood-2010-01-261750","article-title":"Hereditary fibrinogen A alpha-chain amyloidosis: clinical phenotype and role of liver transplantation.","volume":"115","author":"Gillmore","year":"2010","journal-title":"Blood"},{"issue":"Suppl 1","key":"R32-20231002","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3109\/13506129.2012.668503","article-title":"Solid organ transplantation for non-TTR hereditary amyloidosis: report from the 1st International Workshop on the Hereditary Renal Amyloidoses.","volume":"19","author":"Stangou","year":"2012","journal-title":"Amyloid"},{"key":"R33-20231002","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1600-6143.2012.04326.x","article-title":"Renal transplantation in systemic amyloidosis-importance of amyloid fibril type and precursor protein abundance.","volume":"13","author":"Pinney","year":"2013","journal-title":"Am J Transplant"},{"key":"R34-20231002","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2796.2011.02470.x","article-title":"Hereditary lysozyme amyloidosis \u2013 phenotypic heterogeneity and the role of solid organ transplantation.","volume":"272","author":"Sattianayagam","year":"2012","journal-title":"J Intern Med"},{"key":"R35-20231002","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1046\/j.1523-1755.2002.00205.x","article-title":"Hereditary renal amyloidosis caused by a new variant lysozyme W64R in a French family.","volume":"61","author":"Valleix","year":"2002","journal-title":"Kidney Int"},{"key":"R36-20231002","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1080\/13506129.2019.1604336","article-title":"Amyloid in parenchymal organs in gelsolin (AGel) amyloidosis.","volume":"26","author":"Schmidt","year":"2019","journal-title":"Amyloid"},{"key":"R37-20231002","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.kint.2016.11.017","article-title":"Clinical, biopsy, and mass spectrometry findings of renal gelsolin amyloidosis.","volume":"91","author":"Sethi","year":"2017","journal-title":"Kidney Int"},{"key":"R38-20231002","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3109\/07853890.2015.1075063","article-title":"Natural course of Finnish gelsolin amyloidosis.","volume":"47","author":"Nikoskinen","year":"2015","journal-title":"Ann Med"},{"key":"R39-20231002","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/MAJ.0b013e3181a4199c","article-title":"Outcome of renal transplant in hereditary gelsolin amyloidosis.","volume":"337","author":"Shoja","year":"2009","journal-title":"Am J Med Sci"},{"key":"R40-20231002","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1681\/ASN.2005040382","article-title":"Renal apolipoprotein A-I amyloidosis: a rare and usually ignored cause of hereditary tubulointerstitial nephritis.","volume":"16","author":"Gregorini","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R41-20231002","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1111\/j.1600-6143.2006.01507.x","article-title":"Organ transplantation in hereditary apolipoprotein AI amyloidosis.","volume":"6","author":"Gillmore","year":"2006","journal-title":"Am J Transplant"},{"key":"R42-20231002","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1097\/00007890-200104150-00026","article-title":"Clinical and biochemical outcome of hepatorenal transplantation for hereditary systemic amyloidosis associated with apolipoprotein AI Gly26Arg.","volume":"71","author":"Gillmore","year":"2001","journal-title":"Transplantation"},{"key":"R43-20231002","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.ekir.2017.07.009","article-title":"Hereditary renal amyloidosis associated with a novel apolipoprotein A-II variant.","volume":"2","author":"Prokaeva","year":"2017","journal-title":"Kidney Int Rep"},{"key":"R44-20231002","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3109\/13506120309041739","article-title":"Renal transplantation for apolipoprotein AII amyloidosis.","volume":"10","author":"Magy","year":"2003","journal-title":"Amyloid"},{"key":"R45-20231002","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.kint.2016.04.003","article-title":"Clinical, biopsy, and mass spectrometry characteristics of renal apolipoprotein A-IV amyloidosis.","volume":"90","author":"Dasari","year":"2016","journal-title":"Kidney Int"},{"key":"R46-20231002","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1681\/ASN.2015111228","article-title":"Novel type of renal amyloidosis derived from apolipoprotein-CII.","volume":"28","author":"Nasr","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"R47-20231002","doi-asserted-by":"crossref","first-page":"10353","DOI":"10.1038\/ncomms10353","article-title":"D25V apolipoprotein C-III variant causes dominant hereditary systemic amyloidosis and confers cardiovascular protective lipoprotein profile.","volume":"7","author":"Valleix","year":"2016","journal-title":"Nat Commun"},{"key":"R48-20231002","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1056\/NEJMoa070265","article-title":"Natural history and outcome in systemic AA amyloidosis.","volume":"356","author":"Lachmann","year":"2007","journal-title":"N Engl J Med"},{"key":"R49-20231002","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1080\/13506129.2017.1342235","article-title":"Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral centre.","volume":"24","author":"Lane","year":"2017","journal-title":"Amyloid"},{"key":"R50-20231002","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/j.transproceed.2016.04.015","article-title":"Comparative analysis of outcomes of kidney transplantation in patients with AA amyloidosis and chronic glomerulonephritis.","volume":"48","author":"Sahutoglu","year":"2016","journal-title":"Transplant Proc"},{"key":"R51-20231002","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1111\/j.1600-6143.2011.03620.x","article-title":"Renal transplantation in patients with AA amyloidosis nephropathy: results from a French multicenter study.","volume":"11","author":"Kofman","year":"2011","journal-title":"Am J Transplant"},{"key":"R52-20231002","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1001\/archinte.1979.03630470047016","article-title":"Renal transplantation in the amyloidosis of familial Mediterranean fever. Experience in ten cases.","volume":"139","author":"Jacob","year":"1979","journal-title":"Arch Intern Med"},{"key":"R53-20231002","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s10067-012-1992-6","article-title":"Renal transplantation in patients with familial Mediterranean fever.","volume":"31","author":"Erdem","year":"2012","journal-title":"Clin Rheumatol"},{"key":"R54-20231002","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S0272-6386(03)00676-0","article-title":"Long-term outcome of live donor kidney transplantation for renal amyloidosis.","volume":"42","author":"Sherif","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"R55-20231002","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.2215\/CJN.12551214","article-title":"Leukocyte cell-derived chemotaxin 2-associated amyloidosis: a recently recognized disease with distinct clinicopathologic characteristics.","volume":"10","author":"Nasr","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"R56-20231002","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s40620-017-0426-6","article-title":"Pathology and diagnosis of renal non-AL amyloidosis.","volume":"31","author":"Sethi","year":"2018","journal-title":"J Nephrol"},{"key":"R57-20231002","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/ki.2013.558","article-title":"Characterization and outcomes of renal leukocyte chemotactic factor 2-associated amyloidosis.","volume":"86","author":"Said","year":"2014","journal-title":"Kidney Int"},{"key":"R58-20231002","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1053\/j.ajkd.2018.10.016","article-title":"LECT2 amyloidosis in kidney transplantation: a report of 5 cases.","volume":"74","author":"Mejia-Vilet","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"R59-20231002","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1083\/jcb.200303059","article-title":"Heparan sulfate regulates amyloid precursor protein processing by BACE1, the Alzheimer\u2019s beta-secretase.","volume":"163","author":"Scholefield","year":"2003","journal-title":"J Cell Biol"},{"key":"R60-20231002","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1046\/j.1523-1755.2003.00167.x","article-title":"Glycosaminoglycan and proteoglycan inhibit the depolymerization of beta2-microglobulin amyloid fibrils in vitro.","volume":"64","author":"Yamaguchi","year":"2003","journal-title":"Kidney Int"},{"key":"R61-20231002","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/PL00000706","article-title":"Immunoglobulin light chains, glycosaminoglycans, and amyloid.","volume":"57","author":"Stevens","year":"2000","journal-title":"Cell Mol Life Sci"},{"key":"R62-20231002","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1056\/NEJM199702133360703","article-title":"Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans.","volume":"336","author":"Jacobson","year":"1997","journal-title":"N Engl J Med"},{"key":"R63-20231002","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey).","volume":"68","author":"Maurer","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"R64-20231002","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/019131299281752","article-title":"Glomerulopathic light chain-mesangial cell interactions modulate in vitro extracellular matrix remodeling and reproduce mesangiopathic findings documented in vivo.","volume":"23","author":"Herrera","year":"1999","journal-title":"Ultrastruct Pathol"},{"key":"R65-20231002","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1182\/blood.V98.3.714","article-title":"The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden.","volume":"98","author":"Comenzo","year":"2001","journal-title":"Blood"},{"key":"R66-20231002","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1182\/blood-2002-09-2707","article-title":"Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL).","volume":"101","author":"Abraham","year":"2003","journal-title":"Blood"},{"key":"R67-20231002","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1136\/ard.2004.030429","article-title":"Proteolysis of serum amyloid A and AA amyloid proteins by cysteine proteases: cathepsin B generates AA amyloid proteins and cathepsin L may prevent their formation.","volume":"64","author":"R\u00f6cken","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R68-20231002","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/ki.2011.316","article-title":"Medullary amyloidosis associated with apolipoprotein A-IV deposition.","volume":"81","author":"Sethi","year":"2012","journal-title":"Kidney Int"},{"key":"R69-20231002","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/00007890-197711000-00011","article-title":"Transplantation for renal amyloidosis.","volume":"24","author":"Kennedy","year":"1977","journal-title":"Transplantation"},{"key":"R70-20231002","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/00007890-198612000-00005","article-title":"Renal transplantation in 45 patients with amyloidosis.","volume":"42","author":"Pasternack","year":"1986","journal-title":"Transplantation"},{"key":"R71-20231002","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/TP.0000000000001930","article-title":"Patient and kidney allograft survival in recipients with end-stage renal disease from amyloidosis.","volume":"102","author":"Sawinski","year":"2018","journal-title":"Transplantation"},{"key":"R72-20231002","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.2215\/CJN.02740806","article-title":"Light-chain (AL) amyloidosis: diagnosis and treatment.","volume":"1","author":"Sanchorawala","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"R73-20231002","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1093\/ndt\/gfm684","article-title":"Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome.","volume":"23","author":"Bergesio","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"R74-20231002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1523-1755.2002.00085.x","article-title":"Immunoglobulin light chain amyloidosis and the kidney.","volume":"61","author":"Gertz","year":"2002","journal-title":"Kidney Int"},{"key":"R75-20231002","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bbapap.2005.08.014","article-title":"Clinical aspects of systemic amyloid diseases.","volume":"1753","author":"Obici","year":"2005","journal-title":"Biochim Biophys Acta"},{"key":"R76-20231002","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1093\/ndt\/gfp201","article-title":"Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney.","volume":"24","author":"Gertz","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"R77-20231002","first-page":"81","article-title":"Chronic dialysis in patients with systemic amyloidosis: the experience in northern Italy.","volume":"38","author":"Moroni","year":"1992","journal-title":"Clin Nephrol"},{"key":"R78-20231002","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1159\/000168121","article-title":"End-stage renal disease in systemic amyloidosis: clinical course and outcome on dialysis.","volume":"10","author":"Martinez-Vea","year":"1990","journal-title":"Am J Nephrol"},{"key":"R79-20231002","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1001\/archinte.1992.00400230061010","article-title":"Dialysis support of patients with primary systemic amyloidosis. A study of 211 patients.","volume":"152","author":"Gertz","year":"1992","journal-title":"Arch Intern Med"},{"key":"R80-20231002","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1200\/JCO.2010.30.5235","article-title":"Outcome in renal AL amyloidosis after chemotherapy.","volume":"29","author":"Pinney","year":"2011","journal-title":"J Clin Oncol"},{"key":"R81-20231002","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1182\/blood-2017-01-763599","article-title":"Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis.","volume":"130","author":"Kaufman","year":"2017","journal-title":"Blood"},{"key":"R82-20231002","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1080\/14728222.2017.1398235","article-title":"Emerging therapeutic targets currently under investigation for the treatment of systemic amyloidosis.","volume":"21","author":"Nuvolone","year":"2017","journal-title":"Expert Opin Ther Targets"},{"key":"R83-20231002","doi-asserted-by":"crossref","first-page":"E129","DOI":"10.1002\/ajh.25066","article-title":"Predictive value of the new renal response criteria in AL amyloidosis treated with high dose melphalan and stem cell transplantation.","volume":"93","author":"Havasi","year":"2018","journal-title":"Am J Hematol"},{"key":"R84-20231002","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1182\/blood-2007-07-099481","article-title":"Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation.","volume":"110","author":"Sanchorawala","year":"2007","journal-title":"Blood"},{"key":"R85-20231002","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/ki.2014.368","article-title":"Emerging treatments for amyloidosis.","volume":"87","author":"Sayed","year":"2015","journal-title":"Kidney Int"},{"key":"R86-20231002","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy.","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"R87-20231002","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial.","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA"},{"key":"R88-20231002","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial.","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology"},{"key":"R89-20231002","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood.V93.3.1062","article-title":"Long-term survival (10 years or more) in 30 patients with primary amyloidosis.","volume":"93","author":"Kyle","year":"1999","journal-title":"Blood"},{"key":"R90-20231002","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S0002-9343(97)89487-9","article-title":"Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only.","volume":"100","author":"Skinner","year":"1996","journal-title":"Am J Med"},{"key":"R91-20231002","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1182\/blood-2003-12-4192","article-title":"Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study.","volume":"103","author":"Dispenzieri","year":"2004","journal-title":"Blood"},{"key":"R92-20231002","doi-asserted-by":"crossref","first-page":"85","DOI":"10.7326\/0003-4819-140-2-200401200-00008","article-title":"High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study.","volume":"140","author":"Skinner","year":"2004","journal-title":"Ann Intern Med"},{"key":"R93-20231002","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/sj.bmt.1703200","article-title":"An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.","volume":"28","author":"Sanchorawala","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"R94-20231002","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1053\/j.ajkd.2019.04.029","article-title":"Dysproteinemia and the kidney: core curriculum 2019.","volume":"74","author":"Hogan","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"R95-20231002","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1182\/blood-2011-11-390930","article-title":"Cyclophosphamide-bortezomib-dexamethasone (cybord) produces rapid and complete hematologic response in patients with AL amyloidosis.","volume":"119","author":"Mikhael","year":"2012","journal-title":"Blood"},{"key":"R96-20231002","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1093\/ndt\/gfg436","article-title":"No regression of renal AL amyloid in monoclonal gammopathy after successful autologous blood stem cell transplantation and significant clinical improvement.","volume":"18","author":"Zeier","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"R97-20231002","doi-asserted-by":"crossref","first-page":"233","DOI":"10.5414\/CN107162","article-title":"A patient with persistent renal AL amyloid deposition after clinical remission by HDM\/SCT therapy.","volume":"79","author":"Okuyama","year":"2013","journal-title":"Clin Nephrol"},{"key":"R98-20231002","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1182\/blood.V128.22.3261.3261","article-title":"Persistence of minimal residual disease by multiparameter flow cytometry can hinder recovery of organ damage in patients with AL amyloidosis otherwise in complete response.","volume":"128","author":"Palladini","year":"2016","journal-title":"Blood"},{"key":"R99-20231002","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0046-8177(81)80175-X","article-title":"Systemic amyloidosis involving two renal transplants.","volume":"12","author":"Dorman","year":"1981","journal-title":"Hum Pathol"},{"key":"R100-20231002","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1046\/j.1523-1755.2003.00813.x","article-title":"High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease.","volume":"63","author":"Casserly","year":"2003","journal-title":"Kidney Int"},{"key":"R101-20231002","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1111\/j.1600-6143.2005.00920.x","article-title":"Living donor kidney and autologous stem cell transplantation for primary systemic amyloidosis (AL) with predominant renal involvement.","volume":"5","author":"Leung","year":"2005","journal-title":"Am J Transplant"},{"key":"R102-20231002","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1093\/ndt\/gfr067","article-title":"Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation.","volume":"26","author":"Herrmann","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"R103-20231002","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1111\/j.1600-6143.2010.03227.x","article-title":"Solid organ transplantation in AL amyloidosis.","volume":"10","author":"Sattianayagam","year":"2010","journal-title":"Am J Transplant"},{"key":"R104-20231002","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1073\/pnas.92.10.4299","article-title":"Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis.","volume":"92","author":"Tennent","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R105-20231002","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(88)92235-0","article-title":"Diagnostic radionuclide imaging of amyloid: biological targeting by circulating human serum amyloid P component.","volume":"1","author":"Hawkins","year":"1988","journal-title":"Lancet"},{"key":"R106-20231002","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00041552-200211000-00013","article-title":"Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis.","volume":"11","author":"Hawkins","year":"2002","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"R107-20231002","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1053\/j.ackd.2016.07.001","article-title":"Current status of kidney transplant outcomes: dying to survive.","volume":"23","author":"Wang","year":"2016","journal-title":"Adv Chronic Kidney Dis"},{"issue":"Suppl 1","key":"R108-20231002","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/ajt.14557","article-title":"OPTN\/SRTR 2016 annual data report: kidney.","volume":"18","author":"Hart","year":"2018","journal-title":"Am J Transplant"},{"key":"R109-20231002","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.kint.2018.11.003","article-title":"Improved outcomes for kidney transplantation in AL amyloidosis: impact on practice.","volume":"95","author":"Nuvolone","year":"2019","journal-title":"Kidney Int"},{"key":"R110-20231002","doi-asserted-by":"crossref","first-page":"24031","DOI":"10.18632\/oncotarget.15234","article-title":"Activation of NK cells and disruption of PD-L1\/PD-1 axis: two different ways for lenalidomide to block myeloma progression.","volume":"8","author":"Giuliani","year":"2017","journal-title":"Oncotarget"},{"key":"R111-20231002","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1053\/j.ajkd.2016.11.024","article-title":"Acute kidney allograft rejection precipitated by lenalidomide treatment for multiple myeloma.","volume":"69","author":"Lum","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"R112-20231002","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1111\/ajt.12391","article-title":"Fatal cardiac and renal allograft rejection with lenalidomide therapy for light-chain amyloidosis.","volume":"13","author":"Meyers","year":"2013","journal-title":"Am J Transplant"},{"key":"R113-20231002","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1111\/ajt.15499","article-title":"Orthotopic heart transplant rejection in association with immunomodulatory therapy for AL amyloidosis: a case series and review of the literature.","volume":"19","author":"Qualls","year":"2019","journal-title":"Am J Transplant"},{"key":"R114-20231002","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"key":"R115-20231002","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"R116-20231002","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1182\/blood-2014-01-550020","article-title":"Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma.","volume":"123","author":"Martinez-Lopez","year":"2014","journal-title":"Blood"},{"key":"R117-20231002","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41408-018-0086-3","article-title":"Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis.","volume":"8","author":"Kastritis","year":"2018","journal-title":"Blood Cancer J"},{"key":"R118-20231002","first-page":"313","article-title":"Retinol-binding protein, prealbumin, and vitamin A transport.","volume":"5","author":"Goodman","year":"1976","journal-title":"Prog Clin Biol Res"},{"key":"R119-20231002","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/0140-6736(93)93127-M","article-title":"Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis.","volume":"341","author":"Holmgren","year":"1993","journal-title":"Lancet"},{"key":"R120-20231002","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/TP.0000000000000574","article-title":"Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative?","volume":"99","author":"Ericzon","year":"2015","journal-title":"Transplantation"},{"key":"R121-20231002","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/TP.0000000000001021","article-title":"Survival after transplantation in patients with mutations other than Val30Met: extracts from the FAP World Transplant Registry.","volume":"100","author":"Suhr","year":"2016","journal-title":"Transplantation"},{"issue":"1 Suppl","key":"R122-20231002","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1097\/01.tp.0000186910.09213.bf","article-title":"Indications for liver transplantation in patients with amyloidosis: a single-center experience with 11 cases.","volume":"80","author":"Singer","year":"2005","journal-title":"Transplantation"},{"issue":"Suppl 1","key":"R123-20231002","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3109\/13506129.2012.673186","article-title":"Operative risks of domino liver transplantation for the FAP liver donor and the FAP liver recipient.","volume":"19","author":"Azoulay","year":"2012","journal-title":"Amyloid"},{"key":"R124-20231002","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1111\/tri.13326","article-title":"Progression of transthyretin (TTR) amyloidosis in donors and recipients after domino liver transplantation-a prospective single-center cohort study.","volume":"31","author":"Vollmar","year":"2018","journal-title":"Transpl Int"},{"key":"R125-20231002","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1097\/01.TP.0000046526.10003.EC","article-title":"Orthotopic liver transplantation for hereditary fibrinogen amyloidosis.","volume":"75","author":"Zeldenrust","year":"2003","journal-title":"Transplantation"},{"key":"R126-20231002","doi-asserted-by":"crossref","first-page":"S550","DOI":"10.1097\/01.tp.0000543408.60052.c4","article-title":"Renal transplantation in patients with hereditary fibrinogen amyloidosis.","volume":"102","author":"Tavares","year":"2018","journal-title":"Transplantation"},{"key":"R127-20231002","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3109\/13506129.2016.1153465","article-title":"Liver transplant alone without kidney transplant for fibrinogen A\u03b1-chain (AFib) renal amyloidosis.","volume":"23","author":"Fix","year":"2016","journal-title":"Amyloid"},{"key":"R128-20231002","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1093\/ndt\/gfh063","article-title":"Changes in renal function in patients with familial amyloid polyneuropathy treated with orthotopic liver transplantation.","volume":"19","author":"Snanoudj","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"R129-20231002","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/13506129.2016.1238355","article-title":"Increasing amount of amyloid are associated with the severity of clinical features in hereditary gelsolin (AGel) amyloidosis.","volume":"23","author":"Pihlamaa","year":"2016","journal-title":"Amyloid"},{"key":"R130-20231002","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/nep.12108","article-title":"Clinical and pathologic characteristics of hereditary apolipoprotein A-I amyloidosis in Ireland.","volume":"18","author":"Traynor","year":"2013","journal-title":"Nephrology (Carlton)"},{"key":"R131-20231002","article-title":"AA amyloidosis after renal transplantation: an important cause of mortality.","author":"Sarihan","journal-title":"Transplantation"},{"key":"R132-20231002","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/ndt\/gfr381","article-title":"Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney.","volume":"27","author":"Eirin","year":"2012","journal-title":"Nephrol Dial Transplant"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000003170","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T05:49:19Z","timestamp":1696225759000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000003170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,11]]},"references-count":132,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000003170","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2,11]]}}}